Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 2/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.36 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446528 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2DRD2DRD4DRD3ENPP2 | |
| SCHEMBL30299228 | 0.78 | GFER (0.54) | SMN1; SMN2DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL3135711 | 0.76 | HRH3 (0.54) | SIGMAR1L3MBTL1POLBL3MBTL3HRH3 | |
| SCHEMBL422200 | 0.75 | SIGMAR1 (0.56) | DRD2SIGMAR1L3MBTL1POLBL3MBTL3 | |
| SCHEMBL3624985 | 0.75 | SMN1; SMN2 (0.72) | SMN1; SMN2LMNASIGMAR1POLBCXCR4 | |
| SCHEMBL533238 | 0.74 | RAB9A (0.47) | SMN1; SMN2LMNAALDH1A1HPGDL3MBTL1 | |
| SCHEMBL7367987 | 0.72 | SIGMAR1 (0.42) | LMNASIGMAR1ALDH1A1POLBCXCR4 | |
| SCHEMBL3140579 | 0.71 | SIGMAR1 (0.62) | SIGMAR1L3MBTL1POLBL3MBTL3HRH3 | |
| SCHEMBL2105505 | 0.70 | GFER (0.45) | SMN1; SMN2DRD2DRD4DRD3LMNA | |
| SCHEMBL533107 | 0.70 | RAB9A (0.53) | SMN1; SMN2DRD2DRD4DRD3LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9408816-B2 | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy | PHARMACYCLICS LLC (US) | 2016-08-09 | — | — | US | disclosed |
| US-9186347-B1 | Hydroxamates as therapeutic agents | PHARMACYCLICS LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS LLC | 2015-11-12 | — | — | US | disclosed |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8779171-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8389570-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2013-03-05 | — | — | US | disclosed |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8026371-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20080153877-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | PHARMACYCLICS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | disclosed |
| EP-1611088-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS, INC. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2005097770-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | disclosed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | disclosed |
| WO-2004092115-A2 | HYDROXAMATES AS THERAPEUTIC AGENTS | AXYS PHARMACEUTICALS INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | SMN1; SMN2 3363/4885DRD2 4543/4885DRD4 4169/4885 |
| US-20130142758-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | SMN1; SMN2 4315/4885DRD2 4657/4885DRD4 4295/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | SMN1; SMN2 4389/4885DRD2 3832/4885DRD4 3077/4885 |
| US-20140301976-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | SMN1; SMN2 4315/4885DRD2 4657/4885DRD4 4295/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | SMN1; SMN2 4315/4885DRD2 4657/4885DRD4 4295/4885 |
| US-20080153877-A1 | METHOD OF USING HISTONE DEACETYLASE INHIBITORS AND MONITORING BIOMARKERS IN COMBINATION THERAPY | RAD51, HDAC1, HDAC2 | SMN1; SMN2 2126/4885DRD2 4693/4885DRD4 4619/4885 |
| US-20150320718-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | SMN1; SMN2 4315/4885DRD2 4657/4885DRD4 4295/4885 |
| US-20120064032-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | SMN1; SMN2 4315/4885DRD2 4657/4885DRD4 4295/4885 |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | HDAC1, HDAC5, HDAC10 | SMN1; SMN2 2607/4885DRD2 4771/4885DRD4 4725/4885 |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | SMN1; SMN2 3363/4885DRD2 4543/4885DRD4 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.